ATE518546T1 - Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen - Google Patents

Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen

Info

Publication number
ATE518546T1
ATE518546T1 AT08844568T AT08844568T ATE518546T1 AT E518546 T1 ATE518546 T1 AT E518546T1 AT 08844568 T AT08844568 T AT 08844568T AT 08844568 T AT08844568 T AT 08844568T AT E518546 T1 ATE518546 T1 AT E518546T1
Authority
AT
Austria
Prior art keywords
basic protein
myelin basic
compositions containing
protein peptides
medical uses
Prior art date
Application number
AT08844568T
Other languages
German (de)
English (en)
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Application granted granted Critical
Publication of ATE518546T1 publication Critical patent/ATE518546T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
AT08844568T 2007-10-31 2008-10-30 Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen ATE518546T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (1)

Publication Number Publication Date
ATE518546T1 true ATE518546T1 (de) 2011-08-15

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08844568T ATE518546T1 (de) 2007-10-31 2008-10-30 Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen

Country Status (23)

Country Link
US (3) US8623827B2 (enExample)
EP (1) EP2211892B1 (enExample)
JP (1) JP5361895B2 (enExample)
KR (1) KR101570383B1 (enExample)
CN (1) CN101848725B (enExample)
AT (1) ATE518546T1 (enExample)
AU (1) AU2008320657B2 (enExample)
BR (1) BRPI0818302B1 (enExample)
CA (1) CA2703170C (enExample)
CY (1) CY1112620T1 (enExample)
DK (1) DK2211892T3 (enExample)
EA (1) EA017999B1 (enExample)
EC (1) ECSP10010211A (enExample)
HR (1) HRP20110724T1 (enExample)
IL (1) IL204662A (enExample)
MX (1) MX2010004698A (enExample)
MY (1) MY158800A (enExample)
NZ (1) NZ583924A (enExample)
PL (1) PL2211892T3 (enExample)
PT (1) PT2211892E (enExample)
SI (1) SI2211892T1 (enExample)
WO (1) WO2009056833A2 (enExample)
ZA (1) ZA201001748B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US8623827B2 (en) 2007-10-31 2014-01-07 Apitope Technology (Bristol) Limited Myelin basic protein peptide composition
WO2011046462A1 (en) * 2009-10-12 2011-04-21 Angport Limited Composition for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
ES2996275T3 (en) * 2017-01-04 2025-02-12 Worg Pharmaceuticals Zhejiang Co Ltd Therapeutic method using dose escalation protocol for tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
US20210093695A1 (en) * 2017-08-14 2021-04-01 Apitope Technology (Bristol) Limited Method
JP2024518277A (ja) 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SI1311542T1 (sl) * 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
US8623827B2 (en) 2007-10-31 2014-01-07 Apitope Technology (Bristol) Limited Myelin basic protein peptide composition

Also Published As

Publication number Publication date
US8623827B2 (en) 2014-01-07
IL204662A (en) 2013-07-31
PL2211892T3 (pl) 2012-01-31
US9775880B2 (en) 2017-10-03
CN101848725A (zh) 2010-09-29
CN101848725B (zh) 2013-05-22
WO2009056833A2 (en) 2009-05-07
ECSP10010211A (es) 2010-08-31
WO2009056833A3 (en) 2009-11-26
CY1112620T1 (el) 2016-02-10
HK1142803A1 (en) 2010-12-17
EA201070541A1 (ru) 2010-12-30
NZ583924A (en) 2012-06-29
MX2010004698A (es) 2010-05-13
EA017999B1 (ru) 2013-04-30
CA2703170C (en) 2016-10-11
HRP20110724T1 (hr) 2011-12-31
US20140161832A1 (en) 2014-06-12
EP2211892B1 (en) 2011-08-03
SI2211892T1 (sl) 2011-12-30
US9381234B2 (en) 2016-07-05
US20100286054A1 (en) 2010-11-11
PT2211892E (pt) 2011-10-18
BRPI0818302A2 (enExample) 2018-08-21
JP2011500776A (ja) 2011-01-06
MY158800A (en) 2016-11-15
KR101570383B1 (ko) 2015-11-19
ZA201001748B (en) 2011-06-29
DK2211892T3 (da) 2011-10-31
AU2008320657A1 (en) 2009-05-07
BRPI0818302B1 (pt) 2022-04-12
EP2211892A2 (en) 2010-08-04
IL204662A0 (en) 2010-11-30
KR20100036391A (ko) 2010-04-07
US20160263188A1 (en) 2016-09-15
JP5361895B2 (ja) 2013-12-04
CA2703170A1 (en) 2009-05-07
AU2008320657B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
ATE518546T1 (de) Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
EA201001322A1 (ru) Вакцины против хламидиоза
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA201490644A1 (ru) Терапевтические пептиды
EA201592264A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
MX2011010353A (es) Composicion farmaceutica.
EA201070271A1 (ru) Пептиды для получения вакцины
TN2009000291A1 (en) Inhibitors of mek
EA201001883A1 (ru) Мутанты fgf21 и их применение
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201171220A1 (ru) Мутанты fgf21 и их применение
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
MX2018004109A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2211892

Country of ref document: EP